Enzychem to License Technology for Indian Developed DNA COVID-19 Vaccine 'ZyCoV-D'

[Asia Economy Reporter Chunhee Lee] Enzychem Lifesciences will acquire the technology for the DNA COVID-19 vaccine 'ZyCov-D,' which received Emergency Use Authorization (EUA) in India.

On the 25th, Enzychem Lifesciences announced that it signed a manufacturing license technology transfer agreement with Cadila Healthcare of the Zydus Group for the production of 'ZyCov-D,' the world's first plasmid DNA vaccine administered without injection needles, proven effective in humans. ZyCov-D underwent a large-scale clinical trial involving approximately 30,000 participants and recently received emergency use authorization from India's national regulatory authority (DCGI) for patients aged 12 and older. The vaccine is administered using a needle-free injection device that delivers a powerful and fine stream of liquid into the skin, eliminating the need for injection needles.

Under this agreement, Zydus will transfer DNA vaccine manufacturing technology and provide technical support to Enzychem Lifesciences, receiving license fees and royalties in return. Enzychem Lifesciences plans to manufacture the DNA vaccine domestically and export it to low- and middle-income countries (LMICs) in Southeast Asia, Latin America, and Southeast Asian countries aligned with the Korean government's New Southern Policy. Through this partnership, the two companies aim to produce more than 80 million doses of the plasmid DNA vaccine next year.

Son Ki-young, Chairman of Enzychem Lifesciences, said, "Today marks an important milestone for the vaccine consortium embarking on the world's first manufacturing of a DNA vaccine for humans," adding, "With the transferred technology, we can produce vaccines at low cost in a short time." Shavill Patel, CEO of Zydus, also expressed his pleasure in partnering with Enzychem Lifesciences to provide the world's first needle-free plasmid DNA vaccine technology, stating, "Our goal is to provide safe, well-tolerated, and effective vaccines with a new platform capable of fighting COVID-19 to South Korea and several key countries."

This content was produced with the assistance of AI translation services.